MARKET WIREYahoo Finance • 1d ago
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book ValueYahoo Finance report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
Why DMRA Stock advanced +0.51% Today — RQD Quant Desk Flash
$21.60 +0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.58
Damora Therapeutics Inc. (DMRA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $1.33B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DMRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DMRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Damora Therapeutics Inc. (NASDAQ: DMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $21.60 (+0.51% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DMRA ranks #590 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DMRA compare to NKTR and KARD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMRA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and KARD (Kardigan Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B). Among the 5-stock peer group, DMRA leads on earnings multiple (N/A) while DMRA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DMRA?
▼
Per DMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001800315), Damora Therapeutics Inc. generated $590.4M in revenue (+847.3% YoY), -$209.8M in net income, and -$6.7M in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.58 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DMRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY DMRA SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$18.56+11.4% Next Q
27
Q2 (-2Q)Grade E$20.67+6.2% Next Q
30
Q3 (-1Q)Grade E$21.96-1.6% Next Q
32
CurrentGrade D-$21.60-8.5% Hist 90D α
35
Trajectory: E (27) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DMRA Turnaround Squeeze
While DMRA currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.18) and Max Pain ($22.68) forces dealer call-delta covering toward $40.25.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DMRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DMRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DMRA Stock advanced +0.51% Today — RQD Quant Desk Flash
Damora Therapeutics Inc. (DMRA) advanced +0.51% to $21.60, trading at 50% of its 52-week range ($4.95 – $38.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 50% of its 52-week range ($4.95 – $38.33) with RSI-14 at 49.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $21.60 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live DMRA Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Damora Therapeutics, Inc. Estimates – NASDAQ:DMRATradingView report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?Yahoo Finance report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.debelegger.nl • 1d ago
Damora Therapeutics (DMRA) Stock Price, Chart & Analysiswww.debelegger.nl report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHInvesting.com UK • 2d ago
Damora Therapeutics earnings up next as losses expected to widen By Investing.comInvesting.com UK report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
CATALYSTBenzinga • 2d ago
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks MoBenzinga report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 2d ago
DMRA Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 2d ago
Biodesix, Inc. (BDSX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DMRA)
- ✓Walkthrough of DMRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DMRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.70%📐 HORIZONTAL RANGE
2026-11-03O $22.01H $22.01L $21.49C $21.60VOL 339.5K
RES: $40.03SUP: $17.34SMA50: $23.18SMA200: $25.63
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DMRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +847.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on DMRA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DMRA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DMRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DMRA)
Health Care Rank #590 of 1015
⚔️ NKTR vs DMRA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DMRA vs. NKTR, KARD, OMER, AAPG)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Damora Therapeutics Inc. (DMRA) ranks #590 by composite RQD confidence (35/100, grade D-) and #318 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, DMRA leads on earnings valuation at N/A trailing P/E, while DMRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DMRA at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DMRA
ACTIVE
Damora Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | +0.51% | $1.33B | Benchmark Subject |
| NKTR Nektar Therapeutics | E | 20/100 | — | 96.0% | -35.0% | -4.94% | $1.33B | /nktr-vs-dmra → |
| KARD Kardigan Inc. | D | 46/100 | — | — | — | +0.57% | $1.32B | /kard-vs-dmra → |
| OMER Omeros Corporation | D- | 41/100 | — | — | -35.0% | -3.31% | $1.33B | /omer-vs-dmra → |
| AAPG Ascentage Pharma Group International American Depository Shares | D | 45/100 | — | — | — | -6.20% | $1.35B | /aapg-vs-dmra → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001800315 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Damora Therapeutics Inc. (DMRA) reported GAAP revenue of $590.4M (+847.3% vs. FY2024 revenue of $62.3M , and +428.4% cumulative change since FY2023) , GAAP net income of -$209.8M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (+63.9% YoY). On the balance sheet, DMRA closed FY2025 with $260.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $590.4M | -$209.8M | -$6.7M | -$6.7M | $260.5M | — |
| FY2024 (FY) | 2024-12-31 | $62.3M | -$21.4M | -$18.6M | -$18.6M | $17.1M | — |
| FY2023 (FY) | 2023-12-31 | $111.7M | -$38.3M | -$36.9M | -$36.9M | — | — |
3. DMRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DMRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Damora Therapeutics Inc. (NASDAQ: DMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $21.60 (+0.51% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DMRA ranks #590 in composite RQD confidence.
How does DMRA compare to NKTR and KARD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMRA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and KARD (Kardigan Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B). Among the 5-stock peer group, DMRA leads on earnings multiple (N/A) while DMRA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DMRA?
Per DMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001800315), Damora Therapeutics Inc. generated $590.4M in revenue (+847.3% YoY), -$209.8M in net income, and -$6.7M in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DMRA trading relative to its 50-day, 200-day, and 52-week technical levels?
DMRA last traded at $21.60 (+0.51% on volume of 497,331 shares), positioning the stock -6.82% below its 50-day simple moving average ($23.18) and -15.72% below its 200-day simple moving average ($25.63). Across its 52-week range of $4.95 to $38.33, DMRA sits at the 49.9% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.90 to $24.30).
ROARABLE RATING BRIEF • RQD 35/100 (D-)
✓ SEC XBRL & RQD VERIFIED
DMRA — Damora Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Damora Therapeutics Inc. (DMRA) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $21.60 (+0.51% 1D, market capitalization $1.33B).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -0.49%.
- Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Damora Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile lists a market capitalization of $1.4B. Reported revenue in the SEC financials is — for each period shown.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Damora Therapeutics Inc. (DMRA) reported $590.4M in annual revenue (up from $62.3M in FY2024, +847.3% YoY) and -$209.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($111.7M revenue, -$38.3M net income) through FY2025, DMRA scaled operating cash flow to -$6.7M and free cash flow to -$6.7M, backed by $260.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.49% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $4.95 – $38.33 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream suppliers, downstream customers, and sector correlation data are therefore — For a prospective investor, the key second-order watch item is the anticipated widening of losses noted in the risk-watch news item, combined with the cash balance's dependence on continued financing or operating progress. Because the supply-chain graph is empty, no bottleneck mapping can be sourced from this dataset.
- Key Question #1: Can DMRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $590.4M and free cash flow of -$6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is DMRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
DMRA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Damora Therapeutics Inc. (DMRA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value Yahoo Finance report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Damora Therapeutics, Inc. Estimates – NASDAQ:DMRA TradingView report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now? Yahoo Finance report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.debelegger.nl • 1d ago
Damora Therapeutics (DMRA) Stock Price, Chart & Analysis www.debelegger.nl report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investing.com UK • 2d ago
Damora Therapeutics earnings up next as losses expected to widen By Investing.com Investing.com UK report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Benzinga • 2d ago
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Mo Benzinga report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 2d ago
DMRA Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
Biodesix, Inc. (BDSX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Damora Therapeutics Inc. (DMRA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
DMRA Bull vs. Bear Conversation Board — What's Your Call at $21.60?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DMRA 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $27.51 (+28.0%)
📌 Pinned Debate Cash rose to $257.6M in FY 2025 from $14.2M in FY 2024, giving the company a larger liquidity cushion against its operating losses.
Picked up a starter position in DMRA in my $100K Virtual Cash book at $21.49. Cash rose to $257.6M in FY 2025 from $14.2M in FY 2024, giving the company a larger liquidity cushion against its operating losses.. Trading inside a $3.90–$38.33 52-week range with -0.49% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
SectorRotator 🐂 BULL
@QuantViper Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $21.49 and keeping dry powder in case we test $19.99.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $16.98 (-21.0%)
Spot @ $21.49 With $0.0M revenue, ROIC of -35%, and an operating loss of -$210.9M in FY 2025, the company is not generating returns that support its
Fading this rally in DMRA at $21.49. With $0.0M revenue, ROIC of -35%, and an operating loss of -$210.9M in FY 2025, the company is not generating returns that support its $1.36B market value.. With a beta of 1.0 and the stock sitting at $21.49 (52-wk range $3.90–$38.33), the easy multiple expansion is already priced in.